Myasthenia Gravis (MG) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers | Top Key Players are Momenta Pharmaceuticals, Immunovant, Catalyst Pharmaceuticals, Alexion Pharmaceuticals, Inc.,

MG is a neuromuscular disorder, which weakens muscles by decreasing number of acetylcholine receptors at the neuromuscular junction. The disease becomes prominent during adulthood; but symptoms can be observed at any age. People suffering from MG show weakness and drooping of the eyelids, resulting in double vision and excessive fatigue caused after physical work. The disease can be detected by physical examination and diagnostic imaging tests.
Soliris by Alexion Pharmaceuticals Inc. is the only U.S. Food and Drug Administration (USFDA) approved therapeutic drug for the treatment of MG.

Download the sample report at: https://www.pharmaproff.com/request-sample/1226

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route of administration. In this route of administration, entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for MG through intravenous route has shown promising results in clinical studies.

Get the detailed analysis at: https://www.pharmaproff.com/report/myasthenia-gravis-therapeutics-pipeline-analysis

Companies that are involved in developing therapeutics for MG have shown positive clinical results in various phases of drug development. For instance, in December 2018, Ra Pharmaceuticals Inc. announced positive data of phase II trial of zilucoplan for the treatment of patients with MG. The results of the study concluded that treatment with zilucoplan has a favorable safety and tolerability profile, consistent with previously-completed phase I and phase II studies. The majority of adverse events (AEs) reported were mild and not considered by investigators to be related to study drug. There were no serious AEs observed related to treatment with zilucoplan.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1226

Global Market for MG Therapeutics is Expected to Increase Statistically in the next 10 years

Soliris is the only drug used for the treatment of MG. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall MG therapeutics market is expected to grow significantly in the upcoming years.

Some of the key players involved in the development of Myasthenia Gravis (MG) therapeutics in the late- and mid-stage include Momenta Pharmaceuticals Inc., Immunovant Inc., Catalyst Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., ARGENX SE, GlaxoSmithKline plc, Toleranzia AB, and Ra Pharmaceuticals Inc.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.